1-4 of 4
Flora Berisha
Close
Sort by
Journal Articles

FLT3 inhibitors added to induction therapy induce deeper remissions

Clinical Trials & Observations
Mark Levis, Wenge Shi, Ken Chang, Christian Laing, Reinhold Pollner, Christopher Gocke, Emily Adams, Flora Berisha, Jelveh Lameh, Arnaud Lesegretain
Journal: Blood
Blood (2020) 135 (1): 75–78.
https://doi.org/10.1182/blood.2019002180
Published: 2020
Includes: Supplemental data
Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Alexander E. Perl, MD, Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Giovanni Martinelli, MD, Nigel H. Russell, MD, Ken CN Chang, PhD, Derek E. Mires, PharmD, Kazunobu Kato, MD PhD, Yufen Zhang, PhD, Sergey Korkhov, Zhenyu Wang, PhD, Tobias Günnel, PhD, Hiroyuki Sumi, PhD, Takeshi Isoyama, PhD, Arnaud Lesegretain, Flora Berisha, MS, Cedric E. Dos Santos, PhD, Mark J. Levis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 737.
https://doi.org/10.1182/blood-2019-121880
Published: 2019
Journal Articles

Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3 -ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors

Mark J. Levis, MD, Wenge Shi, PhD, Ken CN Chang, PhD, Christian Laing, PhD, Flora Berisha, MS, Emily Adams, BS, MB(ASCP)CM, Christopher D Gocke, MD, Wei Ding, PhD, Kenji Nakamaru, Jelveh Lameh, PhD, Reinhold Pollner, Ken Kobayashi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1459.
https://doi.org/10.1182/blood-2018-99-110438
Published: 2018
Journal Articles

Concordance between Bone Marrow and Peripheral Blood Samples for Assessment of FLT3 Internal Tandem Duplication (ITD) Mutations: Data from Patients Screened for Participation in Quantum-R, a Global, Randomized, Open-Label, Phase 3 Study Examining the Effect of Quizartinib Monotherapy Vs Salvage Chemotherapy on Overall Survival in Patients with FLT3 - ITD - Mutated AML Who Are Refractory to or Have Relapsed after First-Line Therapy

Samer Khaled, MD, Siddhartha Ganguly, MD, Alexander E. Perl, MD, Ken Kobayashi, MD, Flora Berisha, MS, Wei Ding, PhD, Jelveh Lameh, PhD, Giovanni Martinelli, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1424.
https://doi.org/10.1182/blood.V130.Suppl_1.1424.1424
Published: 2017